Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions
BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7131.589 (Published 14 February 1998) Cite this as: BMJ 1998;316:589
- S F T M de Bruijn, senior registrar in neurologya,
- J Stam, professor of neurology (j.stam{at}amc.uva.nl)a,
- M M W Koopman, internistb,
- J P Vandenbroucke, professor of clinical epidemiology for the Cerebral Venous Sinus Thrombosis Study Group.c
- a Department of Neurology, Academic Medical Centre, PO Box 22700, 1100 DE Amsterdam, Netherlands
- b Department of Vascular Medicine, Academic Medical Centre, Amsterdam
- c Department of Clinical Epidemiology, University hospital, Postbus 9600, 2300 RC Leiden, Netherlands
- Correspondence to: Professor Stam
- Accepted 11 November 1997
Abstract
Objective: To investigate whether users of oral contraceptives who are carriers of a hereditary prothrombotic condition (factor V Leiden mutation, protein C, S, or antithrombin deficiency) have an increased risk of cerebral sinus thrombosis.
Design: Comparison of a prospective series of cases of cerebral sinus thrombosis with population data.
Setting: Neurological teaching hospitals from different regions in the Netherlands (cases) and a representative sample of the non-institutionalised Dutch population (controls).
Subjects: 40 women aged 18-54 years with cerebral sinus thrombosis (cases) and 2248 women aged 18-49 years (controls).
Main outcome measure: Current use of oral contraceptives at the time of the thrombosis (cases) or at the time of the questionnaire (controls). Prevalences of a hereditary prothrombotic condition in patients and in the population with odds ratios.
Results: 34 of 40 (85%) women with cerebral sinus thrombosis used oral contraceptives, versus 1007 of 2248 (45%) of the control women; the age adjusted odds ratio was 13 (95% confidence interval 5 to 37). Seven of 36 patients (19%) had a prothrombotic deficiency, versus 7% expected in the population; this corresponds to a threefold to fourfold increase in risk. In women who used oral contraceptives and also carried a prothrombotic defect, the odds ratio for cerebral sinus thrombosis was about 30 relative to women who had neither risk factor.
Conclusion: The use of oral contraceptives and being a carrier of a hereditary prothrombotic condition increase the risk of and interact in a multiplicative way in the development of cerebral sinus thrombosis.
Key messages
The use of oral contraceptives is associated with an increased risk of cerebral venous sinus thrombosis
This risk of cerebral venous sinus thrombosis in women who use oral contraceptives is larger if there is an additional hereditary prothombotic factor (protein C, S, or antithrombin deficiency, factor V Leiden mutation)
The association between oral contraceptives, thrombophilia, and deep vein thrombosis is also valid for cerebral sinus thrombosis
Women do not need to stop using oral contraceptives as the absolute risk of cerebral sinus thrombosis is very small
Footnotes
- Accepted 11 November 1997